nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Addiction/Reward"

 

FDA Approves First Non-Opioid to Treat Opioid Withdrawal Symptoms
May 21, 2018   

The US FDA has approved the first non-opioid treatment for the relief of opioid withdrawal symptoms. The medication, lofexidine hydrochloride (trade name Lucemyra), is an oral, selective alpha-2 adrenergic receptor agonist...
 Continue reading
Illinois Public Health Officials Warning About Synthetic Cannabinoid
April 3, 2018   

Health officials in Illinois are warning people about synthetic cannabinoid products that are causing severe bleeding among users and, in some cases, death...
 Continue reading
NEW Steps from FDA To Mitigate Opioid Overprescribing
February 13, 2018   

Given the widespread epidemic of prescribed opioid use disorder, including an alarming 40 opioid-related overdose deaths per day, the US Food and Drug Administration (FDA) released on January 30, 2018 a revised "blueprint" regarding the prescription of opioids...
 Continue reading (Members only)
Can Cannabis Use Reduce Opioid Use?
February 9, 2018   

Given the ongoing prescription opioid use disorder epidemic as well as the increasing legalization and availability of marijuana, the authors sought to determine whether marijuana use reduced the non-medical use of prescribed opioids...
 Continue reading
New APA Alcohol Guidelines
January 17, 2018   

At a recent meeting, the American Psychiatric Association (APA) Board of Trustees approved the APA Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder (AUD)...
 Continue reading
FDA Allows Marketing of Device to Curb Opioid-Withdrawal Symptoms
November 22, 2017   

The US Food and Drug Administration (FDA) has granted marketing authorization for an electric stimulation device to be used in the reduction of symptoms related to opioid withdrawal...
 Continue reading
Drinking in Adolescence May Alter Brain Development
November 20, 2017   

A recent study found initiating drinking during adolescence was associated with disordered normal brain growth trajectories....
 Continue reading
Increased Risk of Opioid-Related Death in Patients Taking Concomitant Gabapentin
October 16, 2017   

A new study examined the increased risk for opioid-related death in patients taking concomitant prescription opioids and gabapentin...
 Continue reading (Members only)
All Opioids Subject to REMS Requirements
October 3, 2017   

The U.S. Food and Drug Administration (FDA) announced it will broaden the existing Risk Evaluation and Mitigation Strategy (REMS)...
 Continue reading (Members only)
FDA Permits Marketing of Mobile Medical Application for Substance Use Disorders
September 20, 2017   

The US FDA has permitted the marketing of the Reset device, the first mobile medical application to help treat substance use disorders...
 Continue reading
1234
Top of Page